Theravance Biopharma (NASDAQ:TBPH) Reaches New 1-Year High – Here’s What Happened

Theravance Biopharma, Inc. (NASDAQ:TBPH) shares reached a new 52-week high during trading on Tuesday . The stock traded as high as $21.00 and last traded at $20.30, with a volume of 108589 shares changing hands. The stock had previously closed at $20.01.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on TBPH shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Theravance Biopharma in a report on Wednesday, October 8th. Wall Street Zen cut Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. HC Wainwright lifted their price objective on Theravance Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Oppenheimer assumed coverage on Theravance Biopharma in a research report on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 target price for the company. Finally, BTIG Research raised their target price on shares of Theravance Biopharma from $25.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, November 26th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $27.80.

Theravance Biopharma Price Performance

The firm has a market capitalization of $1.03 billion, a PE ratio of 35.82 and a beta of 0.14. The business has a 50-day simple moving average of $18.70 and a 200-day simple moving average of $15.16.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.10. Theravance Biopharma had a return on equity of 12.20% and a net margin of 36.53%.The firm had revenue of $19.99 million for the quarter, compared to the consensus estimate of $19.89 million. On average, research analysts expect that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the business’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total transaction of $582,506.25. Following the transaction, the senior vice president owned 277,695 shares in the company, valued at $5,206,781.25. The trade was a 10.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 6.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Theravance Biopharma

A number of large investors have recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership bought a new position in Theravance Biopharma during the 3rd quarter valued at about $10,611,000. Assenagon Asset Management S.A. grew its stake in shares of Theravance Biopharma by 1,629.4% during the third quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock valued at $6,055,000 after buying an additional 390,735 shares during the last quarter. Hillsdale Investment Management Inc. purchased a new stake in shares of Theravance Biopharma in the third quarter worth approximately $4,536,000. Jefferies Financial Group Inc. raised its holdings in shares of Theravance Biopharma by 1,191.9% in the second quarter. Jefferies Financial Group Inc. now owns 276,887 shares of the biopharmaceutical company’s stock worth $3,054,000 after buying an additional 255,455 shares during the period. Finally, Two Sigma Investments LP lifted its stake in shares of Theravance Biopharma by 1,199.9% during the 3rd quarter. Two Sigma Investments LP now owns 231,272 shares of the biopharmaceutical company’s stock worth $3,377,000 after acquiring an additional 213,480 shares during the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.